{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:34:42Z","timestamp":1776512082456,"version":"3.51.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003975","name":"Israel Cancer Association","doi-asserted-by":"publisher","award":["20171182"],"award-info":[{"award-number":["20171182"]}],"id":[{"id":"10.13039\/501100003975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003975","name":"Israel Cancer Association","doi-asserted-by":"publisher","award":["20160110"],"award-info":[{"award-number":["20160110"]}],"id":[{"id":"10.13039\/501100003975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40264-018-0644-4","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T15:55:23Z","timestamp":1519660523000},"page":"555-564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-4528","authenticated-orcid":false,"given":"Victoria","family":"Rotshild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-3556","authenticated-orcid":false,"given":"Laurent","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd","family":"Zarifeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Masarwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9670-9134","authenticated-orcid":false,"given":"Bruria","family":"Hirsh-Raccah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-7995","authenticated-orcid":false,"given":"Amichai","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-1379","authenticated-orcid":false,"given":"Mordechai","family":"Muszkat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1559-9258","authenticated-orcid":false,"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"644_CR1","unstructured":"OECD. Causes of mortality [Internet]. 2016 [cited 2016 Jul 7]. Available from: http:\/\/stats.oecd.org\/Index.aspx?QueryId=30115."},{"key":"644_CR2","unstructured":"GLOBACAN. Fact Sheets by Population [Internet]. 2016 [cited 2015 Apr 21]. Available from: http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx."},{"key":"644_CR3","unstructured":"Mannino D. Cigarette smoking and other risk factors for lung cancer [Internet]. 2016. Available from: http:\/\/www.uptodate.com\/contents\/cigarette-smoking-and-other-risk-factors-for-lung-cancer?source=see_link."},{"issue":"10","key":"644_CR4","first-page":"1821","volume":"20","author":"GD Friedman","year":"2009","unstructured":"Friedman GD, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. CCC. 2009;20(10):1821\u201335.","journal-title":"CCC"},{"key":"644_CR5","unstructured":"IMI PROTECT. Calcium Channel Blockers and cancer\u2014full text view\u2014ClinicalTrials.gov [Internet]. [cited 2015 Apr 28]. Available from: https:\/\/clinicaltrials.gov\/show\/NCT01587742."},{"issue":"1","key":"644_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","volume":"12","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65\u201382.","journal-title":"Lancet Oncol"},{"issue":"2","key":"644_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00002512-199813020-00002","volume":"13","author":"M Pahor","year":"1998","unstructured":"Pahor M, Furberg CD. Is the use of some calcium antagonists linked to cancer? Drugs Aging. 1998;13(2):99\u2013108.","journal-title":"Drugs Aging"},{"issue":"12","key":"644_CR8","doi-asserted-by":"publisher","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","volume":"7","author":"L Azoulay","year":"2012","unstructured":"Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S. Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS One. 2012;7(12):e50893.","journal-title":"PLoS One"},{"issue":"1","key":"644_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/1097-0142(20000701)89:1<165::AID-CNCR21>3.0.CO;2-G","volume":"89","author":"HT S\u00f8rensen","year":"2000","unstructured":"S\u00f8rensen HT, Olsen JH, Mellemkj\u00f8r L, Thulstrup AM, Steffensen FH, McLaughlin JK, et al. Cancer risk and mortality in users of calcium channel blockers. Cancer. 2000;89(1):165\u201370.","journal-title":"Cancer"},{"issue":"10","key":"644_CR10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2093::AID-CNCR1>3.0.CO;2-E","volume":"85","author":"RP Mason","year":"1999","unstructured":"Mason RP. Effects of calcium channel blockers on cellular apoptosis. Cancer. 1999;85(10):2093\u2013102.","journal-title":"Cancer"},{"issue":"1","key":"644_CR11","first-page":"52","volume":"2","author":"H Yang","year":"2010","unstructured":"Yang H, Zhang Q, He J, Lu W. Regulation of calcium signaling in lung cancer. J Thorac Dis. 2010;2(1):52\u20136.","journal-title":"J Thorac Dis"},{"issue":"4","key":"644_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/sj.onc.1206134","volume":"22","author":"GL Carboni","year":"2003","unstructured":"Carboni GL, Gao B, Nishizaki M, Xu K, Minna JD, Roth JA, et al. CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene. 2003;22(4):615\u201326.","journal-title":"Oncogene"},{"issue":"5","key":"644_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/01.HYP.29.5.1091","volume":"29","author":"JH Olsen","year":"1997","unstructured":"Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL, et al. Cancer risk in users of calcium channel blockers. Hypertension. 1997;29(5):1091\u20134.","journal-title":"Hypertension"},{"key":"644_CR14","doi-asserted-by":"crossref","unstructured":"Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S, et al. Long-term use of angiotensin receptor blockers and the risk of cancer. PloS one [Internet]. L. Azoulay, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, United States; 2012;7(12):e50893. Available from: http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L366284874.","DOI":"10.1371\/journal.pone.0050893"},{"key":"644_CR15","doi-asserted-by":"crossref","unstructured":"Wong CJ, Pagalilauan G, C.J. W, G. P. Primary Care of the Solid Organ Transplant Recipient. Medical Clinics of North America [Internet]. C.J. Wong, Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, United States; 2015;99(5):1075\u2013103. Available from: http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L605766611.","DOI":"10.1016\/j.mcna.2015.05.002"},{"key":"644_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/pds.1656","volume":"17","author":"T Assimes","year":"2008","unstructured":"Assimes T, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf. 2008;17:1039\u201349.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"644_CR17","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<2003::AID-CNCR17>3.0.CO;2-3","volume":"83","author":"KB Michels","year":"1998","unstructured":"Michels KB, Rosner BA, Walker AM, Stampfer MJ, Manson JE, Colditz GA, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of US Women. Cancer. 1998;83(9):2003\u20137.","journal-title":"Cancer"},{"issue":"7","key":"644_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0895-7061(96)00186-0","volume":"9","author":"M Pahor","year":"1996","unstructured":"Pahor M, Guralnik JM, Salive ME, Corti M-C, Carbonin P. HRJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens. 1996;9(7):695\u20139.","journal-title":"Am J Hypertens"},{"issue":"1","key":"644_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0959-8049(02)00157-0","volume":"39","author":"A Beiderbeck-Noll","year":"2003","unstructured":"Beiderbeck-Noll A, Sturkenboom MCJ, van der Linden P, Herings RM, Hofman A, Coebergh JW, et al. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer. 2003;39(1):98\u2013105.","journal-title":"Eur J Cancer"},{"issue":"4","key":"644_CR20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S0735-1097(98)00008-4","volume":"31","author":"S Braun","year":"1998","unstructured":"Braun S, Boyko V, Behar S, Reicher-Reiss H, Laniado S, Kaplinsky E, et al. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. J Am Coll Cardiol. 1998;31(4):804\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"644_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00004872-199816010-00017","volume":"16","author":"DJ Hole","year":"1998","unstructured":"Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, et al. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens. 1998;16(1):119\u201324.","journal-title":"J Hypertens"},{"issue":"6","key":"644_CR22","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0002-9149(99)00113-7","volume":"83","author":"A Sajadieh","year":"1999","unstructured":"Sajadieh A, Storm H, Hansen J. Verapamil and risk of cancer in patients with coronary artery disease. Am J Cardiol. 1999;83(6):1419\u201322.","journal-title":"Am J Cardiol"},{"issue":"9051","key":"644_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(97)80084-0","volume":"349","author":"H Jick","year":"1997","unstructured":"Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet. 1997;349(9051):525\u20138.","journal-title":"Lancet"},{"key":"644_CR24","doi-asserted-by":"crossref","unstructured":"Vezina RM, Lesko SM, Rosenberg L, Shapiro S, R.M. V, S.M. L, et al. Calcium channel blocker use and the risk of prostate cancer. American Journal of Hypertension [Internet]. R.M. Vezina, Slone Epidemiology Unit, Brookline, MA 02446, United States; 1998;11(0895\u20137061):1420\u20135. Available from: http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L29030306.","DOI":"10.1016\/S0895-7061(98)00176-9"},{"issue":"7","key":"644_CR25","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Systematic reviews and meta-analyses CHECK LIST: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"15","key":"644_CR26","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology a proposal for reporting. JAMA. 2000;283(15):2008\u201312.","journal-title":"JAMA"},{"key":"644_CR27","unstructured":"PROSPERO. International Prospective Register of Systematic Reviews Web site, \u201cYork, United Kingdom: Centre for Reviews and Dissemination.\u201d [Internet]. 2017 [cited 2017 Jul 1]. Available from: https:\/\/www.crd.york.ac.uk\/PROSPERO\/searchadvanced.php."},{"key":"644_CR28","unstructured":"Relative Risk Calculator. Relative risk calculator [Internet]. 2016 [cited 2016 Jan 1]. Available from: https:\/\/www.medcalc.org\/calc\/relative_risk.php."},{"key":"644_CR29","unstructured":"Ottawa Hospital Research Institute. Ottawa Scale [Internet]. 2016 [cited 2016 Jan 1]. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"644_CR30","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1093\/eurheartj\/ehu424","volume":"41","author":"BR Costa","year":"2014","unstructured":"Costa BR, Ju P. Statistical tutorials Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. Eur Heart J. 2014;41:3336\u201345.","journal-title":"Eur Heart J"},{"issue":"19","key":"644_CR31","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","volume":"280","author":"J Zhang","year":"1998","unstructured":"Zhang J, Yu KF. What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690\u20131.","journal-title":"JAMA"},{"issue":"3","key":"644_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1289\/ehp.0901402","volume":"118","author":"N Guha","year":"2010","unstructured":"Guha N, Merletti F, Steenland NK, Altieri A, Cogliano V, Straif K. Lung cancer risk in painters: a meta-analysis. Environ Health Perspect. 2010;118(3):303\u201312.","journal-title":"Environ Health Perspect"},{"issue":"3","key":"644_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.annepidem.2007.10.005","volume":"18","author":"AK Chaturvedi","year":"2008","unstructured":"Chaturvedi AK, Mbulaiteye SM, Engels EA. Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol. 2008;18(3):230\u20134.","journal-title":"Ann Epidemiol"},{"issue":"8","key":"644_CR34","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1128\/AAC.48.8.2787-2792.2004","volume":"48","author":"SL Spruance","year":"2004","unstructured":"Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48(8):2787\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"644_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18773\/austprescr.2008.008","volume":"31","author":"I Scott","year":"2008","unstructured":"Scott I. Interpreting risks and ratios in therapy trials. Aust Prescr. 2008;31:12\u20136.","journal-title":"Aust Prescr"},{"key":"644_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. 1st ed. Hoboken: Wiley; 2009.","edition":"1"},{"key":"644_CR37","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Regression in meta-analysis. In: Comprehensive meta analysis manual. 2015. https:\/\/www.meta-analysis.com\/downloads\/MRManual.pdf. Accessed 14 Feb 2018."},{"issue":"13","key":"644_CR38","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","volume":"279","author":"L Rosenberg","year":"1998","unstructured":"Rosenberg L. Calcium channel blockers and the risk of cancer. JAMA. 1998;279(13):1000 (American Medical Association).","journal-title":"JAMA"},{"issue":"9026","key":"644_CR39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(96)04277-8","volume":"348","author":"M Pahor","year":"1996","unstructured":"Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348(9026):493\u20137.","journal-title":"Lancet"},{"issue":"7040","key":"644_CR40","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/bmj.312.7040.1215","volume":"312","author":"N Black","year":"1996","unstructured":"Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215\u20138 (Clinical research ed).","journal-title":"BMJ"},{"issue":"4","key":"644_CR41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492\u20139.","journal-title":"Am J Epidemiol"},{"issue":"12","key":"644_CR42","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.2337\/dc12-0788","volume":"35","author":"S Suissa","year":"2012","unstructured":"Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665\u201373.","journal-title":"Diabetes Care"},{"issue":"3","key":"644_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1357","volume":"16","author":"S Suissa","year":"2007","unstructured":"Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"644_CR44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","volume":"108","author":"I Sipahi","year":"2011","unstructured":"Sipahi I, Chou J, Mishra P, Debanne SM, Simon DI, Fang JC. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol. 2011;108:294\u2013301.","journal-title":"Am J Cardiol"},{"issue":"4","key":"644_CR45","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/HJH.0b013e3282f3ef5e","volume":"26","author":"CI Coleman","year":"2008","unstructured":"Coleman CI, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens. 2008;26(4):622\u20139.","journal-title":"J Hypertens"},{"key":"644_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ijcard.2014.10.028","volume":"179","author":"MCS Wong","year":"2015","unstructured":"Wong MCS, Tam WWS, Lao XQ, Wang HHX, Kwan MWM, Cheung CSK, et al. The incidence of cancer deaths among hypertensive patients in a large Chinese population: a cohort study. Int J Cardiol. 2015;179:178\u201385.","journal-title":"Int J Cardiol"},{"issue":"5","key":"644_CR47","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1089\/neu.2010.1746","volume":"29","author":"J Lu","year":"2012","unstructured":"Lu J, Marmarou A, Lapane KL, IMPACT Investigators. Impact of GOS misclassification on ordinal outcome analysis of traumatic brain injury clinical trials. J Neurotrauma. 2012;29(5):719\u201326.","journal-title":"J Neurotrauma"},{"issue":"10","key":"644_CR48","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0002-9149(90)90351-Z","volume":"66","author":"Danish Study Group","year":"1990","unstructured":"Danish Study Group. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II\u2013DAVIT II). Am J Cardiol. 1990;66(10):779\u201385.","journal-title":"Am J Cardiol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-018-0644-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0644-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0644-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:44:54Z","timestamp":1628617494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-018-0644-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1007\/s40264-018-0644-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"26 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Victoria Rotshild, Laurent Azoulay, Majd Zarifeh, Reem Masarwa, Bruria Hirsh- Raccah, Amichai Perlman, Mordechai Muszkat, and Ilan Matok have no conflicts of interest that are directly relevant to the content of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was partially supported by the Israel Cancer Association and Esther Blinko Fund. The study funder has no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. All the researchers are independent of the founders.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}